Cargando…
Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.
With the aim of increasing the dose intensity of chemotherapy in breast cancer, 14 patients with stage II-IV breast cancer were treated with FEC chemotherapy at 2 week intervals together with granulocyte colony-stimulating factor (G-CSF) 5 micrograms kg-1 s.c. on days 2-14. Five of six patients comp...
Autores principales: | Bissett, D., Jodrell, D., Harnett, A. N., Habeshaw, T., Kaye, S. B., Evans, D., Williams, M., Canney, P. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033830/ https://www.ncbi.nlm.nih.gov/pubmed/7540038 |
Ejemplares similares
-
Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats
por: Papalois, Apostolos E., et al.
Publicado: (2019) -
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
por: Rossi, Luigi, et al.
Publicado: (2013) -
Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004) -
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
por: Kelly, S, et al.
Publicado: (2009) -
Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor
Publicado: (1994)